Levomepromazin Terapia

Levomepromazine, the active ingredient in Levomepromazin Terapia, is a phenothiazine antipsychotic presented as an oral formulation for oral use. It is employed to manage schizophrenia, acute psychosis, severe agitation, and nausea or vomiting in adult patients. GNH USA supplies Levomepromazin Terapia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levomepromazine is a phenothiazine antipsychotic that acts on dopaminergic pathways to treat several psychiatric and gastrointestinal conditions.

Schizophrenia: reduces psychotic symptoms such as delusions, hallucinations and thought disorder. Acute psychosis: helps control sudden onset of severe psychotic episodes. Severe agitation: calms intense restlessness and aggressive behavior. Nausea and vomiting: alleviates refractory nausea, especially in palliative care settings.

Levomepromazine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Sedation or drowsiness - Orthostatic hypotension - Dry mouth and other anticholinergic effects - Constipation or gastrointestinal discomfort - Blurred vision

Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Tardive dyskinesia or other movement disorders - Severe hypotension or cardiac arrhythmia - Agranulocytosis or blood dyscrasias - Seizures - Elevated liver enzymes or hepatic dysfunction

When prescribing Levomepromazin Terapia, clinicians should consider several safety measures.

Dose adjustment in elderly: start low and monitor for excessive sedation. Monitor cardiovascular status: risk of orthostatic hypotension and arrhythmia. Assess for extrapyramidal symptoms: watch for tremor, rigidity, or dyskinesia. Avoid use in patients with known hypersensitivity to phenothiazines. Store at room temperature: keep in the original container, protect from moisture and light.

Levomepromazin Terapia can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Concurrent use with other dopamine antagonists: increased risk of severe extrapyramidal symptoms. - Combination with CNS depressants (e.g., benzodiazepines, opioids): enhanced sedation and respiratory depression. - Co‑administration with strong anticholinergic agents: additive anticholinergic burden.

Moderate Interactions (Monitor Closely): - Use with antihypertensives: may potentiate hypotensive effect. - Combination with QT‑prolonging drugs: increased risk of cardiac arrhythmia. - Interaction with CYP2D6 inhibitors: may raise levomepromazine plasma levels.